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Abstract
Background: Bioresorbable scaffolds (BRS) were considered to be beneficial for coronary bifurcation 
lesions regarding the avoidance of lateral branch opening incarceration after complete absorption. How-
ever, data is limited in this setting. The aim of this meta-analysis was to evaluate the short (6-month) 
and medium-term (1-year) outcomes of BRS in patients with coronary bifurcation lesions. 
Methods: PubMed, EMBASE, Web of Science, Cochrane library databases were searched to find the 
studies of BRS implantation in patients with coronary bifurcation lesions. The effective outcome was 
target lesion revascularization. The safety outcomes included major adverse cardiovascular events, 
target vessel revascularization, myocardial infarction, definite or probable scaffold thrombosis, and 
cardiac death.
Results: A total of 1204 patients involved in 12 studies were included. The pooled estimate rate of 
target lesion revascularization as efficacy outcome was highly consistent between 6-month and 1-year 
follow-up, which was 4.74% (95% CI 2.36–9.54%, I2 = 41.5%, p = 0.14) and 4.37% (95% CI 
3.05–5.69%, I2 = 4.6%, p = 0.39). The pooled estimated rate of major adverse cardiovascular events 
as safety outcome was 5.50% and 7.31% for both 6-month and 1-year follow-up. The pooled estimated 
rate of target vessel revascularization, myocardial infarction, definite or probable scaffold thrombosis, 
and cardiac death at 1-year follow-up was 5.92%, 2.52%, 1.69%, and 0.42%. 
Conclusions: The application of BRS for coronary bifurcation lesions is acceptable in efficacy 
outcome, but the high rate of scaffold thrombosis remains of concern (Registered by PROSPERO, 
CRD42019140341). (Cardiol J)
Key words: bioresorbable scaffolds, coronary bifurcation lesions, percutaneous coronary 
intervention, meta-analysis 
Introduction 
Bifurcation lesions are common complex 
coronary artery lesions, accounting for 15–20% 
of percutaneous coronary intervention (PCI), and 
are also one of the most challenging lesions in 
interventional cardiology from the point of view 
for procedural success rate and long-term cardiac 
events [1]. Drug-eluting stents (DES) are cur-
rently recommended for the treatment of coronary 
bifurcation lesions [2]. However, the DES can lead 
to inflammation, poor adherence and impaired 
vasodilation, which may also limit the possibility 
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addition, the risks of late stent thrombosis and in-
stent restenosis are still the major factors affecting 
the efficacy of coronary artery disease especially 
coronary bifurcation lesions [3, 4].
The emergence of bioresorbable scaffolds 
(BRS), which can be traced back to 1980s may be 
conducive to this problem with the following ad-
vantages: shorter arterial healing time than DES 
implantation, late lumen expansion can reduce the 
risk of restenosis and avoidance of long-term jailing 
for side branch stent after complete resorption of 
scaffold wire within 2–3 years following implanta-
tion [4]. Meanwhile, it is believed that restoration 
of vascular patency may be more important for 
treatment of coronary bifurcation lesions in the 
absence of permanent implants [5]. Additional 
potential advantages include easier imaging (car-
diac computed tomography or magnetic resonance 
imaging) and increased lumen area [6].
The applications of BRS are being extended 
to more complex lesions in the real-world study. 
However, there is still a lack of randomized con-
trolled trials for coronary bifurcation lesions; the 
available data are limited to observational studies of 
conclusion conflict [7, 8]. The current expert con-
sensus only provided a limited recommendation for 
the application of this new technology in coronary 
bifurcation lesions [1, 2, 9]. Given the advantages 
and clinical setting of BRS, a hypothesis to be ben-
eficial for patients with coronary bifurcation lesions 
was established. Therefore, this systematic review 
and meta-analysis was designed to evaluate the 
efficacy and safety of BRS for the short- (6-month) 
and medium-term (1-year) in patients with those. 
Methods
Search strategy
The present systematic review and meta-
analysis was performed according to the Preferred 
Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) consensus statement 
[10] and the Meta-analysis of Observational Stud-
ies in Epidemiology (MOOSE) consensus state-
ment [11]. PubMed, EMBASE, Web of Science, 
Cochrane library databases were searched with the 
following keywords: “coronary bifurcation lesion*” 
AND “bioresorbable scaffold*” OR “bioresorbable 
vascular stent*” (Suppl. File S1) with no language 
restrictions from inception to September 21, 2019. 
The references from relevant articles were scanned 
for additional studies not identified in the initial 
database search. An automated reminder from the 
PubMed was set up to track the latest publications. 
All reports were independently screened by two 
investigators (X.Y. Liang and Y. Li) to determine 
whether they met the inclusion criteria and any 
disagreement was resolved by consultation. The 
study protocol was registered in PROSPERO 
(CRD42019140341). 
Selection criteria
The inclusion criteria were as follows: (1) pa-
tients with at least one coronary bifurcation lesion 
(de novo bifurcation lesion involving a side-branch 
≥ 2 mm by visual estimation in diameter); (2) at 
least 1 BRS implanted; (3) at least 9 patients were 
included in the study; (4) trials reported clinical 
outcomes for at least 6 months; (5) included at 
least 1 clinical outcome, such as target lesion revas-
cularization (TLR), major adverse cardiovascular 
events (MACE), target vessel revascularization 
(TVR), myocardial infarction (MI), definite or 
probable scaffold thrombosis (ST) or cardiac death.
The exclusion criteria included: (1) ex-
perimental studies on animals; (2) case report, 
conference abstract, review or expert opinions; 
(3) incomplete description (no complete report 
for patient characteristics and clinical outcomes of 
coronary bifurcation lesions); (4) duplicate publica-
tion or duplicate studies (if duplicate studies were 
identified, only the most exhaustive and recent 
reports were retained).
Data extraction
Baseline characteristics, lesion and procedural 
characteristics for patients, as well as numbers of 
events, were independently extracted from the 
original publications by 4 investigators (X.Y. Liang, 
Y. Li, W.J. Zhang, and X. Qiao). Divergences were 
resolved through discussions with the third party 
(Z.L. Wang). 
Outcomes and definitions
The effective outcome was TLR, defined as 
any repeated PCI or coronary artery bypass graft-
ing (CABG) for the segment of previously treated 
or in the adjacent 5 mm. The safety outcomes were 
MACE, TVR, any MI, definite or probable ST, and 
cardiac death. The MACE was defined according 
to the definitions of the original trials. The TVR 
was defined as repeat PCI or CABG in the target 
vessel. The MI was defined according to the uni-
versal definition [12]. The definite or probable ST 
was classified according to the Academic Research 
Consortium criteria [13]. Deaths that could not 
be attributed to another cause was regarded as 
cardiac death. 
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Quality assessment 
Depending on the type of study included, the 
Newcastle-Ottawa scale checklist [14] and the 
Joanna Briggs Institute Critical Appraisal Checklist 
for Case Series (https://joannabriggs.org/research/
critical-appraisal-tools.html) were used to assess 
the quality of non-randomized studies and case 
series. The quality of all studies was independently 
evaluated by 2 investigators (X.Y. Liang and Y. Li) 
and any dispute was settled by a third party through 
negotiations (Z.L. Wang). Furthermore, GRADE-
profiler 3.2.2 was performed to appraise the quality 
of the evidence as high, moderate, low or very low 
grades [15]. As analyses were based on previously 
published studies, ethical approval and patient 
consent were not required.
Statistical analysis
Statistical analysis was performed on the 
pooled data of all included studies. The metaprop 
command was used to calculate combined rate with 
95% confidence interval (95% CI). The normality 
test was employed for untransformed proportion 
(PRAW) and the rate transformed by Natural 
Logar Transformed Proportion, Logit Transformed 
Proportion, Arcsine Transformed Proportion or 
Freeman-Tukey Double Arcsine Transformed be-
fore the metaprop analysis, and the method close 
to the normal distribution was selected according 
to the results. Meta-analyses of dichotomous vari-
ables were expressed as odds ratio (OR) and 95% 
CI. Heterogeneity was assessed by the Higgins 
I2 test, and random-effects model was applied to 
calculate the statistic effects. Publication bias was 
evaluated by visual estimation of funnel plots and 
the Egger’s test at the p < 0.05 level of signifi-
cance. The sensitivity analysis was performed by 
omitting one study from the analysis at a time. The 
subgroup analysis was utilized to explore the effect 
of different conditions (acute coronary syndrome 
[ACS] or not, diabetes mellitus [DM] or not) on 
outcomes. The p-value threshold of two-tailed 
significance was 0.05. Analyses were performed 
with R 3.6.1 (R Foundation for Statistical Comput-
ing, Vienna, Austria and Stata SE 14.0 (StataCorp 
LP, College Station, Texas). 
Results
Search results and characteristics
At first, 532 articles were retrieved, which 
were reduced to 144 studies after screening the 
title and abstract. Finally, 12 studies are included 
in the quantitative synthesis after excluding most 
unrelated studies (Fig. 1) [7, 8, 16–25]. Among 
them, the Desolve 150 BRS (Elixir, US) was used 
in one study [22], while others used the second-
generation everolimus-eluting bioresorbable vas-
cular scaffolds (ABSORB; Abbott Vascular, Santa 
Clara, CA, USA). A total of 1,204 patients met 
the inclusion criteria and were included, of whom 
1,014 (84.2%) were male patients, 573 (47.6%) 
patients with ACS and 369 (30.7%) patients with 
DM in Table 1. The lesion and procedure features 
are listed in Table 2. The quality assessments for 
studies are reported in Supplementary Tables S1 
and S2. GRADE quality assessment is provided in 
Supplementary Table S3.
The effective outcome
Five studies provided data on the effective out-
come of TLR at 6-month follow-up and the pooled 
estimate rate of TLR is 4.74% (95% CI 2.36–9.54%, 
I2 = 41.5%, p = 0.14; Fig. 2). A significant asym-
metry was observed in the funnel plot by visual 
estimation (Suppl. Fig. S1a). However, the pub-
lication bias was not detected by the Egger’s test 
(p = 0.81). The sensitivity analysis shows that the 
pooled estimate rate was reduced from 4.74% to 
3.53% and heterogeneity of the remaining studies 
had changed significantly (I2 = 0%) when a study 
was omitted (Suppl. Fig. S2). The effective out-
come for 1 year was followed-up in 8 studies, which 
shows that the pooled estimate rate of TLR was 
4.37% (95% CI 3.05–5.69%, I2 = 4.6%, p = 0.39) 
(Fig. 2). For this outcome, no asymmetry is identi-
fied in the funnel plot by visual estimation (Suppl. 
Fig. S1b), and no significant publication bias was 
found by the Egger’s test (p = 0.11). 
The safety outcomes
The safety outcomes are presented (Fig. 3). 
The pooled estimate rate of MACE was 5.50% 
(95% CI 0.56–10.45%, I2 = 41.2%, p = 0.15) at 
6-month follow-up and 7.31% (95% CI 4.69–9.92%, 
I2 = 36.9%, p = 0.16) at 1-year follow-up. The 
sensitivity analysis shows that the pooled estimate 
rate of MACE at 6-month follow-up had decreased 
from 5.50% to 3.89% and heterogeneity of the re-
maining studies had changed significantly (I2 = 0%) 
after omitting one study (Suppl. Fig. S2b). The 
initial pooled estimate rates of TVR and MI at 
1-year follow-up were 5.92% (95% CI 3.62–8.22%, 
I2 = 15.5%, p = 0.31) and 2.52% (95% CI 1.32– 
–3.73%, I2 = 28.6%, p = 0.19). The pooled estimate 
rate was 1.69% (95% CI 0.80–2.58%, I2 = 0%, 
p = 0.49) for the definite or probable ST and 
0.42% (95% CI 0–0.95%, I2 = 0%, p = 0.97) for 
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cardiac death without publication bias at 1-year 
follow-up. The effects of the simple and complex 
strategies on the definite or probable ST are ex-
tracted and analyzed in 5 studies, which shows that 
there was no statistical significance between the 
simple and complex strategies (OR = 0.86, 95% CI 
0.248–2.624; I2 = 0%, p = 0.981; Fig. 4).
Subgroup analysis
Two subgroup analyses were performed ac-
cording to the median proportion of patients with 
ACS and DM in the 12 studies included. The ACS 
was stratified according to whether the median 
proportion exceeded 40.35%, the DM was strati-
fied according to whether the median proportion 
exceeded 28.85%. The results showed that the 
pooled estimate rate of MI, definite or probable ST 
and cardiac death was increased in patients with 
ACS and DM (3.82% vs. 1.54%, 2.52% vs. 1.28% 
and 0.66% vs. 0.35% for the subgroup of ACS vs. 
non-ACS, respectively; 4.04% vs. 2.03, 3.01% vs. 
1.54% and 1.06% vs. 0.40% for the subgroup of DM 
vs. non-DM, respectively), which increase nearly 
or more than twice (Suppl. Figs. S3 and S4). The 
effect on TLR, MACE and TVR is not significant 
for both ACS and DM subgroups (Suppl. Figs. 
S5 and S6).
Discussion
According to available research, this is the first 
systematic review and meta-analysis involving 
the application of BRS for patients with coronary 
bifurcation lesions. The major findings are as 
follows: (1) the pooled estimated rate of TLR as 
the effective outcome of BRS for patients with 
those is acceptable at short- and medium-term 
follow-up; (2) a majority of the safety outcomes 
(MACE, TVR, MI and cardiac death) have reached 
the safety effect size; (3) the rate of definite or 
probable ST remains a concern. However, these 
findings are only based on observational stud-
ies with very low GRADE quality. Therefore, 
this estimate is very uncertain, and additional 
Records identied through
database searching
 (n = 532)
Additional records identied
through other sources 
(n = 0)
Records after duplicates removed
 (n = 312)
Records screened
 (n = 312)
Full-text articles assessed for eligibility
 (n = 144)
Studies included in qualitative synthesis
 (n = 12)
Studies included in qualitative synthesis
(meta-analysis)
 (n = 12)
Records excluded
 (n =168)
Full-text articles excluded, with reasons
(n = 132):
— 42 basic trial
— 25 incomplete date
— 23 review
— 17 conference abstract
— 11 case report
— 6 experence or corresponce
— 6 design of relevate study





















Figure 1. Flow chart of study selection. 
4 www.cardiologyjournal.org






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cardiology Journal 20XX, Vol. XX, No. X
randomized trials are required to provide higher 
quality evidence. 
The BRS has the characteristic of complete 
absorption and is known as the fourth revolution in 
the history of coronary intervention, which changed 
the long-term problem of permanent implantation 
and achieved complete revascularization/restora-
tion of vascular patency. The Igaki-Tamai stent 
was the first biodegradable stent to be included in 
human trials with long-term (> 10 year) clinical 
outcomes and intravascular ultrasound data, which 
had acceptable MACE and ST rates without stent 
recoil and vessel remodeling [26]. It revealed 
a promising early result. More than 10 BRS with 
different backbone, different coating drug dose, 
different strut thickness, different vessel coverage 
area and different complete resorption time have 
been tested in clinical practice to date. However, 
these scaffolds are still in clinical research and lack 
of powerful evidence. Most experience came from 
bioresorbable vascular scaffolds (BVS) of Abbott, 
whereas poor clinical results for ST and low market 
share led to its delisting in 2017. This appears to 
place a veil over the use of BRS. However, two 
recently published randomized controlled trials 
showed optimistic results. One was the ABSORB IV 
trial [27], which showed that BVS resulted in 
non-inferior rates of target lesion failure and angina 
pectoris compared with metallic DES, another was 
the implanted NeoVas BRS that indicted non-inferi-
or to metallic DES for angiographic in-segment late 
loss and clinical outcomes [28]. The NeoVas BRS is 
a new generation BRS, which could elute sirolimus 
from a poly-D, l-lactide coating. Nonetheless, these 
do not include coronary bifurcation lesions. 
Currently, there is limited evidence to inves-
tigate the clinical results of BRS in coronary bifur-
cation lesions, although Stankovic and Lassen [5] 
believed that BRS might better provide profit in 
this specific lesion. The incidence of TLR and 
majority safety outcomes for BRS was acceptable 
compared with first- and second-generation DES in 
coronary bifurcation lesions 29, 30]. Another nota-
ble problem is that the results were obtained on the 
basis that the side branch was more than at least 
2 mm, regardless of intervention or not. The BRS 
was designed with increased strut thickness, which 
is easier to protrude into the side branch and oc-
clude it. Therefore, the coronary bifurcation lesions 
should be selected cautiously when BRS was used, 
which were supported by studies from Muramatsu 
et al. [31] and Ojeda et al. [21]. The rate of MACE 
was significantly lower at 1-year follow-up in this 
meta-analysis than that of the second-generation 
DES (6.91% vs. 12.1%), which might be due to 
different event definitions rather than an obvious 
advantage. It should also be emphasized that the 
incidence of definite or probable ST implanted BRS 
was significantly higher than that of second-genera-
tion DES (1.61% vs. 0.7% with 1st-stent, 1.4% with 
2nd-stent). The same results were drawn in simple 
lesions, which needs to be addressed to reduce 
Figure 2. Primary endpoints for studies included; CI — confidence interval; TLR — target lesion revascularization.
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Figure 3. Secondary endpoints for studies included; CI — confidence interval; MACE — major adverse cardiac events; 
MI — myocardial infarction; TVR — target vessel revascularization; ST — scaffold thrombosis.
the rate of definite or probable ST. First of all, this 
result can be improved by more appropriate lesion 
selection and standard implantation techniques 
(pre-dilation, sizing and post-dilation technique). 
In addition, the provisional strategy was recom-
mended for bifurcation lesions according to present 
consensus and guidelines [1, 2]. This study did 
not provide further recommendations for simple 
and complex strategies, but the simple strategy 
(single stent or provisional strategy) is obviously 
more popular. Previous research has shown that 
premature discontinuation of antiplatelet therapy 
exacerbated risk of scaffold thrombosis [8]. The 
2018 ESC/EACTS Guidelines recommended that 
dual antiplatelet therapy should be considered 
for at least 12 months and up to the presumed 
full absorption of BRS [2]. Although the BRS was 
designed to reduce the duration of long-term an-
8 www.cardiologyjournal.org
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tiplatelet therapy, this may occur after complete 
stent degradation. The result of a registry study, 
BVS LATE (NCT02939872), intended to evaluate 
the optimal duration of antiplatelet therapy after 
BVS implantation is to be expected. Preliminary 
subgroup analysis showed that ACS and DM were 
risk factors of partial safety outcomes, which 
were similar to the coronary bifurcation lesions 
substudy from GHOST EU Registry [20]. This 
suggests a more conservative approach to patient 
selection.
Nevertheless, the results must be interpreted 
cautiously before there is insufficient evidence to 
support them. Firstly, considering the difference 
of baseline characteristics and the BRS types, as 
well as varied definitions of clinical outcome, the 
event rates might be influenced. Secondly, most of 
these results were from European, and may require 
data from more regional and ethnic populations to 
determine whether the results can be extrapolated. 
In addition, these data were only observational 
studies from specific clinical centers which had 
better implantation technology and higher opera-
tion success rates. Furthermore, the proportion of 
intravascular imaging varies greatly, which has an 
important impact on of procedure and incidence of 
postoperative events, and is an important reason 
for the differences in the results of the studies. 
Therefore, it also needs to be evaluated by rand-
omized controlled trials. Meanwhile, BRS should 
be implanted cautiously in patients with a high risk 
of bleeding who cannot tolerate dual antiplatelet 
therapy for 12 months. Furthermore, the quality 
of evidence and the strength of recommendation 
for the studies included were very low according 
to GRADE criteria, which was because of limita-
tions of the single-arm observational study design, 
lack of indirect evidence from a control group, 
and inaccurate results due to small sample sizes. 
However, the purpose of this meta-analysis was to 
summarize the evidence, it should not be widely 
used in clinical practice without further evidence. 
Limitation of the study
The limitations of this meta-analysis should 
be considered. Firstly, the studies included were 
single-arm or observational studies with small 
sample sizes, most of which were single-center 
data, which significantly decreased the level 
of evidence for study. Secondly, the absorbable 
scaffolds implanted in the meta-analysis were 
not uniform, with BVS dominating, and no mag-
nesium — BRS were included. These differences 
may affect the results of study. Thirdly, the data 
of subgroup analysis were based on the median 
of patients with DM and ACS in the single-arm 
study, which was not supported by the specific 
evidence, the results should be interpreted care-
fully. Fourthly, due to the limitations of current 
clinical studies, the duration of dual antiplatelet 
therapy and the optimal strategy in this study had 
not been clearly explained. Lastly, longer-term 
results after the stents complete absorption have 
also not been reported.
Conclusions
This meta-analysis shows that the application 
of BRS for coronary bifurcation lesions is accept-
able in efficacy outcome and most safety outcomes, 
but the high rate of ST remains a concern. The 
efficacy and safety of BRS on coronary bifurcation 
Figure 4. Effects of simple and complex strategies on definite or probable scaffold thrombosis for studies included 
(aData from [24]; bData from [25]); CI — confidence interval; OR — odds ratio.
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lesions should be explored in large-scale rand-
omized controlled trials in the future.
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